CompaniesOtherUpdated Oct 14, 2026

Soufflé Therapeutics

Private. Soufflé Therapeutics is a biotechnology company aimed at advancing the next generation of therapies to help people live healthier lives.

Last round: $135M Series B
Backed by: Juvia Group
Launched: 2021
People: 10

Overview

Updated Oct 14, 2026

Every fact carries a numbered source. Where we can't source something, it says so.

Identity fields from the company record are sourced where a source is recorded; those have no number.

Headquarters: Watertown, MA³
Website: souffletx.com opens in a new tab³
Stage: Series B · as of 2026-10-13²
Founded: 2021 · as of 2025-10-07¹
Sector: Not recorded
Geography: Watertown, MA

Funding

How much has Soufflé Therapeutics raised?

Rounds and backers, each sourced.

Rounds

2026-10-13
Series B · $135M raised²
Led by Juvia Group

Who backs Soufflé Therapeutics?

Juvia GroupLed the Series B, 2026-10-13²

Opportunities For accredited investors

Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.

For accredited investors

Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.

No live opportunities right now. Accredited investors are notified first when one opens.

Create an accredited profile

A vehicle is never smaller than $1,000,000.

People

Who founded and leads Soufflé Therapeutics?

Names and titles only, each sourced.

Victor KotelianskiFounder³
Vadim DudkinFounding Chief Technology Officer³
Robert LangerFounder³
Srividya SubramanianSVP, General Counsel³
Daniel AndersonFounder³
Susan LangerChief Business Officer³
Roman BogoradSVP, Discovery Biology³
Amir NashatFounder, Director and CEO³
Marino ZerialFounder³
Brad PenteluteFounder³

Sources

Every claim on this page traces to one of these. The numbers match the citations above.

1
Soufflé Therapeutics Gets Venture, Pharma Backing for Genetic Medicines opens in a new tabFounded · accessed Oct 14, 2026
2
Soufflé Therapeutics Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline Progress opens in a new tabStage, Funding · accessed Oct 14, 2026
3
Soufflé Therapeutics | Redefining how medicines are made. opens in a new tabHeadquarters, Website, People · accessed Oct 14, 2026